Drug intelligence / Profile preview

simvastatin + fenebrutinib

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

Simvastatin + fenebrutinib is a combination of two small molecule drugs. Simvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular events by inhibiting the enzyme responsible for cholesterol synthesis in the liver[1][2]. Fenebrutinib (GDC-0853) is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), developed for autoimmune and inflammatory diseases as well as certain hematologic malignancies[5][6][8]. The combination has been studied in drug-drug interaction trials but is not an approved therapeutic regimen.

Brand names: Zocor
Other names: simvastatinfenebrutinib

Targets

BTK (Bruton tyrosine kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on simvastatin + fenebrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + fenebrutinib.

Explore the full profile